Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A Dawson, Rab K Prinjha, Antje Dittmann, George Giotopoulos, Marcus Bantscheff, Wai-In Chan, Samuel C Robson, Chun-wa Chung, Carsten Hopf, Mikhail M Savitski, Carola Huthmacher, Emma Gudgin, Dave Lugo, Soren Beinke, Trevor D Chapman, Emma J Roberts, Peter E Soden, Kurt R Auger, Olivier Mirguet, Konstanze Doehner Show all
Nature | NATURE PUBLISHING GROUP | Published : 2011
Awarded by Medical Research Council
We thank S. J. Dawson, A. Bannister, S. Anand and all members of the Huntly and Kouzarides laboratories. We are grateful to H. Doehner, the NCRI AML trials biobank and A. Giles for the provision of patient samples. We acknowledge D. Huang for the BCL2 expression plasmid, L. Gordon for supplying fluorescence resonance energy transfer data and R. Woodward, C. Delves, E. Jones and P. Holmes for protein production. J. Witherington, N. Parr, S. Baddeley and J. Seal provided compound selectivity data. We thank N. Deeks and L. Cutler for providing sample and PK data analysis. We acknowledge K. Smitheman and A. Wyce for help with the cellular analysis of the BET inhibitors, P. Grandi for suggestions and discussion, S. Chan for biophysical assay data, and members of the Epinova team for discussion and suggestions. We thank staff at the ESRF at Grenoble for beamline assistance. We thank T. Werner for assistance with mass spectrometry experiments and data analysis, and the members of the Cellzome Biochemistry, Mass Spectrometry, and IT teams for outstanding expertise and diligence. This work was supported by a Wellcome-Beit Intermediate Clinical Fellowship to M. A. D. The Huntly lab is funded by the Medical Research Council (UK), Leukaemia Lymphoma Research (UK), the Wellcome Trust, The Leukemia & Lymphoma Society of America, Cancer Research UK (CRUK) and the NIHR Cambridge Biomedical Research Centre. This work in the Kouzarides laboratory was funded by a programme grant from Cancer Research UK (CRUK).